2019 Form 10-K Financial Statement
#000156459020014162 Filed on March 30, 2020
Income Statement
| Concept | 2019 | 2018 Q4 | 2018 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $8.720M | $1.290M | $5.180M |
| YoY Change | 68.34% | 39.62% | |
| % of Gross Profit | |||
| Research & Development | $34.91M | $8.380M | $31.77M |
| YoY Change | 9.89% | 23.99% | |
| % of Gross Profit | |||
| Depreciation & Amortization | $1.330M | $300.0K | $1.240M |
| YoY Change | 7.26% | -10.14% | |
| % of Gross Profit | |||
| Operating Expenses | $43.63M | $9.670M | $36.95M |
| YoY Change | 18.09% | 25.97% | |
| Operating Profit | -$43.63M | -$36.95M | |
| YoY Change | 18.09% | ||
| Interest Expense | |||
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | $1.292M | $240.0K | $800.0K |
| YoY Change | 61.5% | 263.64% | |
| Pretax Income | -$42.34M | -$9.430M | -$36.15M |
| YoY Change | 17.12% | 24.13% | |
| Income Tax | $660.0K | ||
| % Of Pretax Income | |||
| Net Earnings | -$43.00M | -$9.430M | -$36.15M |
| YoY Change | 18.95% | 24.13% | |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$1.890M | -$405.6K | -$1.589M |
| COMMON SHARES | |||
| Basic Shares Outstanding | |||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 | 2018 Q4 | 2018 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $77.40M | $63.80M | |
| YoY Change | 21.32% | 34.32% | |
| Cash & Equivalents | $77.40M | $63.80M | $63.80M |
| Short-Term Investments | |||
| Other Short-Term Assets | $3.100M | $1.300M | |
| YoY Change | 138.46% | 85.71% | |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $80.50M | $65.06M | $65.10M |
| YoY Change | 23.66% | 35.06% | |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $3.700M | $4.159M | $4.200M |
| YoY Change | -11.9% | 121.05% | |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $400.0K | $389.0K | $400.0K |
| YoY Change | 0.0% | 100.0% | |
| Total Long-Term Assets | $4.100M | $4.548M | $4.500M |
| YoY Change | -8.89% | 104.55% | |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $80.50M | $65.06M | $65.10M |
| Total Long-Term Assets | $4.100M | $4.548M | $4.500M |
| Total Assets | $84.60M | $69.61M | $69.60M |
| YoY Change | 21.55% | 38.1% | |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.100M | $1.771M | $1.800M |
| YoY Change | -38.89% | 63.64% | |
| Accrued Expenses | $3.600M | $2.488M | $2.500M |
| YoY Change | 44.0% | 66.67% | |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $9.300M | $4.643M | $4.600M |
| YoY Change | 102.17% | 43.75% | |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | |
| YoY Change | |||
| Other Long-Term Liabilities | $2.200M | $1.000M | |
| YoY Change | 120.0% | 11.11% | |
| Total Long-Term Liabilities | $2.200M | $1.000M | |
| YoY Change | 120.0% | 11.11% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $9.300M | $4.643M | $4.600M |
| Total Long-Term Liabilities | $2.200M | $1.000M | |
| Total Liabilities | $11.50M | $5.600M | |
| YoY Change | 105.36% | 33.33% | |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$119.0M | ||
| YoY Change | |||
| Common Stock | $22.44M | ||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $73.10M | -$97.11M | $64.00M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $84.60M | $69.61M | $69.60M |
| YoY Change | 21.55% | 38.1% |
Cashflow Statement
| Concept | 2019 | 2018 Q4 | 2018 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$43.00M | -$9.430M | -$36.15M |
| YoY Change | 18.95% | 24.13% | |
| Depreciation, Depletion And Amortization | $1.330M | $300.0K | $1.240M |
| YoY Change | 7.26% | -10.14% | |
| Cash From Operating Activities | -$35.47M | -$9.210M | -$32.95M |
| YoY Change | 7.65% | 21.51% | |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $888.0K | -$1.650M | -$3.500M |
| YoY Change | -125.37% | 212.5% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $50.00K | ||
| YoY Change | |||
| Cash From Investing Activities | -$843.0K | -$1.650M | -$3.500M |
| YoY Change | -75.91% | 212.5% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $34.72M | $266.0K | |
| YoY Change | 12953.01% | -99.12% | |
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 49.90M | 22.62M | 52.73M |
| YoY Change | -5.37% | 75.2% | |
| NET CHANGE | |||
| Cash From Operating Activities | -35.47M | -9.210M | -32.95M |
| Cash From Investing Activities | -843.0K | -1.650M | -3.500M |
| Cash From Financing Activities | 49.90M | 22.62M | 52.73M |
| Net Change In Cash | 13.59M | 11.76M | 16.28M |
| YoY Change | -16.56% | 775.32% | |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$35.47M | -$9.210M | -$32.95M |
| Capital Expenditures | $888.0K | -$1.650M | -$3.500M |
| Free Cash Flow | -$36.36M | -$7.560M | -$29.45M |
| YoY Change | 23.46% | 13.28% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q4 | dei |
Entity Public Float
EntityPublicFloat
|
187400000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
77383000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1264000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
65062000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4159000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2488000 | |
| CY2018Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
161111000 | |
| CY2018Q4 | us-gaap |
Receivable From Officers And Directors For Issuance Of Capital Stock
ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock
|
598000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-4000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-118953000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-97113000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
69610000 | |
| CY2019Q4 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
| CY2018Q4 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
0 | |
| CY2018Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
104018468 | |
| CY2019Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
0 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
389000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
69610000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1771000 | |
| CY2018 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-4000 | |
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
24000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
50000000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
878413 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
878413 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
1170000 | |
| CY2019 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
660000 | |
| CY2019Q4 | rapt |
Working Capital
WorkingCapital
|
71300000 | |
| CY2018Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
16415281 | |
| CY2018 | rapt |
Increase Decrease In Prepaid Expenses And Other Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherLongTermAssets
|
691000 | |
| CY2019Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
0 | |
| CY2018Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
16415281 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
50000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
21833037 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
21833037 | |
| CY2019 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
34910000 | |
| CY2018 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
31767000 | |
| CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8719000 | |
| CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5180000 | |
| CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
43629000 | |
| CY2018 | us-gaap |
Operating Expenses
OperatingExpenses
|
36947000 | |
| CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-43629000 | |
| CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-36947000 | |
| CY2019 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1292000 | |
| CY2018 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
800000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-42337000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-36147000 | |
| CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
660000 | |
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-42997000 | |
| CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36147000 | |
| CY2018 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-36151000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
58.09 | |
| CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
622289 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
266000 | |
| CY2018 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
17000 | |
| CY2018 | rapt |
Interest On Promissory Notes From Related Parties For Purchase Of Common Stock
InterestOnPromissoryNotesFromRelatedPartiesForPurchaseOfCommonStock
|
10000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
34721000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
175490000 | |
| CY2019 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
174000 | |
| CY2019 | rapt |
Paydown Of Promissory Notes From Related Parties For Purchase Of Common Stock
PaydownOfPromissoryNotesFromRelatedPartiesForPurchaseOfCommonStock
|
73000 | |
| CY2019 | rapt |
Forgiveness Of Promissory Notes From Related Parties For Purchase Of Common Stock
ForgivenessOfPromissoryNotesFromRelatedPartiesForPurchaseOfCommonStock
|
353000 | |
| CY2019 | rapt |
Interest On Promissory Notes From Related Parties For Purchase Of Common Stock
InterestOnPromissoryNotesFromRelatedPartiesForPurchaseOfCommonStock
|
2000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
2051000 | |
| CY2019 | us-gaap |
Profit Loss
ProfitLoss
|
-42997000 | |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-36147000 | |
| CY2019 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1330000 | |
| CY2018 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1237000 | |
| CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2051000 | |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1170000 | |
| CY2019 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
35000 | |
| CY2018 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-17000 | |
| CY2019 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-24000 | |
| CY2018 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
0 | |
| CY2019 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-20000 | |
| CY2018 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
14000 | |
| CY2019 | rapt |
Increase Decrease In Prepaid Expenses And Other Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherLongTermAssets
|
1859000 | |
| CY2018 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
0 | |
| CY2019 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
736000 | |
| CY2018 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1437000 | |
| CY2019 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-1256000 | |
| CY2018 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-38000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-35474000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-32953000 | |
| CY2019 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
45000 | |
| CY2019 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
888000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-843000 | |
| CY2019 | us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
14379000 | |
| CY2018 | us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
52468000 | |
| CY2019 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
34721000 | |
| CY2018 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
0 | |
| CY2019 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
802000 | |
| CY2018 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
266000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
49902000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
52734000 | |
| CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
13585000 | |
| CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
16281000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
63798000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
47517000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
77383000 | |
| CY2018 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | |
| CY2019 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | |
| CY2018 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
753000 | |
| CY2019 | rapt |
Convertible Preferred Stock Converted To Common Stock
ConvertiblePreferredStockConvertedToCommonStock
|
175490000 | |
| CY2019 | rapt |
Net Cash Forgiveness Of Promissory Notes From Related Parties For Purchase Of Common Stock
NetCashForgivenessOfPromissoryNotesFromRelatedPartiesForPurchaseOfCommonStock
|
397000 | |
| CY2019 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of the Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RAPT Therapeutics, Inc. (<font style="color:#000000;">“</font>RAPT<font style="color:#000000;">”</font> or the <font style="color:#000000;">“</font>Company<font style="color:#000000;">”</font>) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. In May 2019, the Company changed its name from FLX Bio, Inc. to RAPT Therapeutics, Inc. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is located in South San Francisco, California. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Financings</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the Company completed its initial public offering (“IPO”), pursuant to which the Company issued an aggregate of 3,427,360 shares of its common stock at an offering price of $12.00 per share for net proceeds of $34.7 million after deducting underwriting discounts and other offering related costs. Immediately prior to the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock converted into 17,467,184 shares of the Company’s common stock.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of its IPO, the Company’s certificate of incorporation was amended and restated to provide for 500,000,000 authorized shares of common stock with a par value of $0.0001 per share and 50,000,000 authorized shares of preferred stock with a par value of $0.0001 per share.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed an underwritten follow-on public offering (“Follow‑on Offering”) of 2,500,000 shares of its common stock issued at an offering price of $30.00 per share. The shares issued in the Follow-on Offering generated approximately $69.7 million in net proceeds after deducting underwriting discounts and other offering related costs.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Management Plans </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2019, the Company incurred a net loss of $43.0 million and used $35.5 million of cash in operations. At December 31, 2019, the Company had cash and cash equivalents of $77.4 million and working capital of $71.3 million.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company’s current cash and cash equivalents, including the net proceeds of approximately $69.7 million from the Follow-on Offering in February 2020, will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.<font style="color:#000000;"> </font></p> | |
| CY2019 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, common stock valuation and stock-based compensation. Actual results could differ from such estimates or assumptions. </p> | |
| CY2019 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all the Company’s cash and cash equivalents are held by financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds.</p> | |
| CY2019 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
2000000 | |
| CY2018 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
1800000 | |
| CY2019 | us-gaap |
Loss Contingency Accrual Payments
LossContingencyAccrualPayments
|
0 | |
| CY2018Q4 | us-gaap |
Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
|
170000000 | |
| CY2018Q4 | rapt |
Aggregate Indebtedness Maximum
AggregateIndebtednessMaximum
|
5000000 | |
| CY2019 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | |
| CY2018 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
9766000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
9128000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
6059000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4969000 | |
| CY2019Q4 | rapt |
Accrued Research And Clinical Development Expenses
AccruedResearchAndClinicalDevelopmentExpenses
|
1353000 | |
| CY2018Q4 | rapt |
Accrued Research And Clinical Development Expenses
AccruedResearchAndClinicalDevelopmentExpenses
|
519000 | |
| CY2019Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
1779000 | |
| CY2018Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
1433000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
192000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
182000 | |
| CY2018Q4 | rapt |
Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
|
202000 | |
| CY2019Q4 | rapt |
Accrued Lab Supplies Current
AccruedLabSuppliesCurrent
|
29000 | |
| CY2018Q4 | rapt |
Accrued Lab Supplies Current
AccruedLabSuppliesCurrent
|
80000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
289000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
72000 | |
| CY2015Q2 | rapt |
Operating Lease Expiration Year
OperatingLeaseExpirationYear
|
2022-05 | |
| CY2015Q2 | us-gaap |
Tenant Improvements
TenantImprovements
|
800000 | |
| CY2018Q2 | rapt |
Additional Square Feet Area Of Laboratory And Office Facilities Under Lease
AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
|
6378 | |
| CY2018Q2 | rapt |
Increased Area Of Leased Premises
IncreasedAreaOfLeasedPremises
|
36754 | |
| CY2018Q2 | rapt |
Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
|
2026-11 | |
| CY2015Q2 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2015Q2 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
| CY2018Q4 | us-gaap |
Tenant Improvements
TenantImprovements
|
1400000 | |
| CY2018Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
2400000 | |
| CY2019Q3 | rapt |
Additional Square Feet Area Of Laboratory And Office Facilities Under Lease
AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
|
6378 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1602000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1969000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2037000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2109000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
6579000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
14296000 | |
| CY2019 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
The holders of the Company’s common stock have one vote for each share of common stock held by them | |
| CY2019 | rapt |
Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
|
1 | |
| CY2019 | us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | |
| CY2018 | us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | |
| CY2019Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
2522034 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
|
0 | |
| CY2019 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2051000 | |
| CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1170000 | |
| CY2019Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
7900000 | |
| CY2019 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y6M | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-41301000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-36034000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-1036000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-113000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-42337000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-36147000 | |
| CY2019 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
660000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
-0.0063 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
-0.0060 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.0297 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.0368 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
|
-0.0123 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.2318 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.2413 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.0049 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.0005 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.0156 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
29014000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
20810000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3378000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
105000 | |
| CY2019Q4 | rapt |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
|
837000 | |
| CY2018Q4 | rapt |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
|
448000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
215000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
50000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
34702000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
24791000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
34605000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
4636000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
24791000 | |
| CY2019Q4 | rapt |
Deferred Tax Liabilities Gross Depreciation And Amortization
DeferredTaxLiabilitiesGrossDepreciationAndAmortization
|
97000 | |
| CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
97000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2019 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
9800000 | |
| CY2018 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
8700000 | |
| CY2018Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1281000 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
789000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
19000 | |
| CY2019 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
466000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
473000 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1747000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2019 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
4404486 | |
| CY2018 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
866348 | |
| CY2019 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
9.89 | |
| CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
58.09 | |
| CY2019 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1313468 | |
| CY2018 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
17109160 |
